The ICM research agenda on intensive care unit-acquired weakness

Nicola Latronico, Margaret Herridge, Ramona O Hopkins, Derek Angus, Nicholas Hart, Greet Hermans, Theodore Iwashyna, Yaseen Arabi, Giuseppe Citerio, E. Wesley Ely, Jesse Hall, Sangeeta Mehta, Kathleen Puntillo, Johannes Van den Hoeven, Hannah Wunsch, Deborah Cook, Claudia Dos Santos, Gordon Rubenfeld, Jean-Louis Vincent, Greet Van den Berghe, Elie Azoulay, Dale M Needham, Nicola Latronico, Margaret Herridge, Ramona O Hopkins, Derek Angus, Nicholas Hart, Greet Hermans, Theodore Iwashyna, Yaseen Arabi, Giuseppe Citerio, E. Wesley Ely, Jesse Hall, Sangeeta Mehta, Kathleen Puntillo, Johannes Van den Hoeven, Hannah Wunsch, Deborah Cook, Claudia Dos Santos, Gordon Rubenfeld, Jean-Louis Vincent, Greet Van den Berghe, Elie Azoulay, Dale M Needham

Abstract

We present areas of uncertainty concerning intensive care unit-acquired weakness (ICUAW) and identify areas for future research. Age, pre-ICU functional and cognitive state, concurrent illness, frailty, and health trajectories impact outcomes and should be assessed to stratify patients. In the ICU, early assessment of limb and diaphragm muscle strength and function using nonvolitional tests may be useful, but comparison with established methods of global and specific muscle strength and physical function and determination of their reliability and normal values would be important to advance these techniques. Serial measurements of limb and respiratory muscle strength, and systematic screening for dysphagia, would be helpful to clarify if and how weakness of these muscle groups is independently associated with outcome. ICUAW, delirium, and sedatives and analgesics may interact with each other, amplifying the effects of each individual factor. Reduced mobility in patients with hypoactive delirium needs investigations into dysfunction of central and peripheral nervous system motor pathways. Interventional nutritional studies should include muscle mass, strength, and physical function as outcomes, and prioritize elucidation of mechanisms. At follow-up, ICU survivors may suffer from prolonged muscle weakness and wasting and other physical impairments, as well as fatigue without demonstrable weakness on examination. Further studies should evaluate the prevalence and severity of fatigue in ICU survivors and define its association with psychiatric disorders, pain, cognitive impairment, and axonal loss. Finally, methodological issues, including accounting for baseline status, handling of missing data, and inclusion of patient-centered outcome measures should be addressed in future studies.

Keywords: Disability; Fatigue; Muscle weakness; Myopathy; Pain; Physical impairment; Polyneuropathy.

References

    1. Intensive Care Med. 2015 Dec;41(12):2138-48
    1. Lancet. 2009 May 30;373(9678):1874-82
    1. Neurology. 2013 Nov 19;81(21):1827-31
    1. Am J Respir Crit Care Med. 2013 Feb 1;187(3):238-46
    1. Am J Respir Crit Care Med. 2012 Apr 15;185(8):835-41
    1. Intensive Care Med. 2016 Nov;42(11):1790-1793
    1. Am J Respir Crit Care Med. 2013 Sep 1;188(5):567-76
    1. JAMA. 2016 Jun 28;315(24):2694-702
    1. PLoS One. 2013 Sep 30;8(9):e75696
    1. Intensive Care Med. 2014 Apr;40(4):528-38
    1. JAMA. 2013 May 22;309(20):2130-8
    1. Crit Care Med. 2012 Jul;40(7):2182-9
    1. Am J Respir Crit Care Med. 2016 Aug 1;194(3):299-307
    1. Crit Care Med. 2012 Jan;40(1):79-89
    1. JAMA. 2016 Jun 7;315(21):2340-1
    1. Crit Care Med. 2015 Aug;43(8):1603-11
    1. Am J Respir Crit Care Med. 2015 Nov 1;192(9):1080-8
    1. Crit Care Med. 2014 Apr;42(4):849-59
    1. Crit Care. 2016 Oct 29;20(1):354
    1. Crit Care. 2011;15(2):R84
    1. Lancet Respir Med. 2016 Jul;4(7):566-573
    1. Am J Respir Crit Care Med. 2014 May 15;189(10):1214-24
    1. Crit Care Med. 2016 Jun;44(6):e362-9
    1. Thorax. 2016 Sep;71(9):812-9
    1. Am J Respir Crit Care Med. 2014 Dec 15;190(12):1437-46
    1. Crit Care Med. 2016 Jun;44(6):1145-52
    1. Am J Respir Crit Care Med. 2016 May 15;193(10):1101-10
    1. Crit Care. 2013 May 29;17(3):R101
    1. Crit Care Med. 2013 Oct;41(10):2396-405
    1. JPEN J Parenter Enteral Nutr. 2016 Aug;40(6):795-805
    1. Am J Respir Crit Care Med. 2017 Mar 1;195(5):652-662
    1. Am J Respir Crit Care Med. 2017 Jan 1;195(1):57-66
    1. J Physiol. 2016 Aug 1;594(15):4371-88
    1. Am J Respir Crit Care Med. 2011 Apr 15;183(8):1037-42
    1. JAMA Intern Med. 2015 Apr;175(4):523-9
    1. Am J Respir Crit Care Med. 2013 Feb 15;187(4):387-96
    1. Crit Care. 2013 Jul 24;17(4):R156
    1. N Engl J Med. 2013 Oct 3;369(14):1306-16
    1. Am J Respir Crit Care Med. 2013 Jan 1;187(1):20-7
    1. N Engl J Med. 2011 Apr 7;364(14):1293-304
    1. JAMA. 2015 Mar 17;313(11):1101-2
    1. Lancet Respir Med. 2013 Oct;1(8):621-629
    1. Lancet Neurol. 2011 Oct;10(10):931-41
    1. Crit Care Med. 2001 Sep;29(9):1678-82
    1. Intensive Care Med. 2017 Feb;43(2):171-183
    1. Am J Respir Crit Care Med. 2016 Dec 1;194(11):1337-1348
    1. Am J Respir Crit Care Med. 2012 Aug 15;186(4):302-4
    1. Intensive Care Med. 2017 Jan;43(1):29-38
    1. Intensive Care Med. 2017 Jan;43(1):39-47
    1. Crit Care. 2016 Jul 31;20(1):231
    1. F1000Res. 2014 Jun 11;3:127
    1. Nat Commun. 2015 Dec 15;6:10145
    1. Am J Respir Crit Care Med. 2016 Oct 1;194(7):831-844
    1. Am J Respir Crit Care Med. 2016 Oct 1;194(7):821-830
    1. Am J Respir Crit Care Med. 2015 Jun 15;191(12):1464-7
    1. Crit Care Med. 2016 May;44(5):859-68
    1. JAMA. 2017 Feb 7;317(5):530-531
    1. JAMA. 2013 Oct 16;310(15):1591-600
    1. Crit Care Med. 2012 Feb;40(2):647-50
    1. BMJ. 2016 May 17;353:i2375
    1. Chest. 2016 Jul;150(1):148-63
    1. Crit Care. 2016 Sep 28;20(1):305
    1. Intensive Care Med. 2016 Oct;42(10):1557-1566
    1. Crit Care Med. 2015 Apr;43(4):897-905
    1. Lancet. 2016 Oct 1;388(10052):1377-1388
    1. Crit Care Med. 2016 Jun;44(6):1129-37
    1. BMJ. 2013 Mar 19;346:f1532
    1. N Engl J Med. 2015 Jun 18;372(25):2398-408
    1. JAMA. 2015 Mar 10;313(10):1055-7

Source: PubMed

3
Sottoscrivi